Clinical Trials Logo

Clinical Trial Summary

There is currently no specific treatment available for COVID-19 disease. There is an urgent need for affordable, worldwide available and safe agents for treatment of COVID-19. Dietary supplements Curcumin, Quercetin and Vitamin D are widely used to boost the body's immune system against infections. In the present study, the combination of dietary supplements curcumin, quercetin and vitamin D, all contained in one soft capsule (Nasafytol), will be investigated for early COVID-19 symptoms improvement and viral clearance in outpatients.


Clinical Trial Description

The ongoing pandemic of COVID-19 has taken the lives of 4.3 million people worldwide and continues to take further lives. There is currently no specific treatment available for COVID-19. Reported scientific evidence suggest that it is highly unlikely that a single agent will be able to treat COVID-19, but a combination of different agents targeting different pathways appears to be required to treat COVID-19. Dietary supplements curcumin and quercetin have demonstrated strong antioxidant, broad-spectrum anti-viral and anti-inflammatory properties including against the respiratory tract infections. They are widely used to boost the immunity against infections and keeping healthy life-style. Results from recent clinical trials also suggest that people with vitamin D deficiency are possibly at higher risk of getting COVID-19 infection than those with sufficient vitamin D levels. A number of studies also reported significantly lower vitamin D levels in patients who developed severe COVID-19 disease. The purpose of the present study is to investigate the potential clinical benefits of combination of curcumin, quercetin and vitamin D (all contained in a single soft capsule, Nasafytol) as adjunct treatment with standard for care, for early symptoms improvement and viral clearance in COVID-19 in non-hospitalised patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05008003
Study type Interventional
Source Ayub Teaching Hospital
Contact Dr. Zeeshan Haroon, MBBS
Phone + 92 317 5564317
Email [email protected]
Status Recruiting
Phase N/A
Start date September 5, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Not yet recruiting NCT05047640 - COVID-19 3rd Dose Vaccine in Transplant Patients Phase 3
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Enrolling by invitation NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Active, not recruiting NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Recruiting NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Active, not recruiting NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Recruiting NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection